Acute Heart failure - Pipeline Insight, 2024

This “Acute Heart failure - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Heart failure Understanding

Acute Heart failure: Overview

Acute heart failure (AHF), also known as acute decompensated heart failure or cardiac failure, is not a single disease entity, but rather a syndrome of the worsening of signs and symptoms reflecting an inability of the heart to pump blood at a rate commensurate to the needs of the body at normal filling pressure. AHF is often not acute in onset, typically developing gradually over the course of days to weeks, where the acuity is a function of the need for urgent or emergent therapy due to the severity of these signs or symptoms. AHF may be the result of a primary disturbance in the systolic or diastolic function of the heart or of abnormal venous or arterial vasoconstriction, but generally represents an interaction of multiple factors, including volume overload. The majority of patients have decompensation of chronic heart failure (CHF) and consequently much of the discussion of the pathophysiology, presentation, and diagnosis of CHF is directly relevant to an understanding of AHF. A patient with AHF typically presents with some combination of increased congestion and, less frequently, decreased peripheral perfusion. In addition to disturbances in oxygenation due to pulmonary edema, renal dysfunction is a frequent manifestation of AHF and reflects the multisystem nature of this disease.

Acute Heart failure - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Heart failure pipeline landscape is provided which includes the disease overview and Acute Heart failure treatment guidelines. The assessment part of the report embraces, in depth Acute Heart failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Heart failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Acute Heart failure.
• In the coming years, the Acute Heart failure market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Acute Heart failure R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Acute Heart failure treatment market. Several potential therapies for Acute Heart failure are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Acute Heart failure market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Acute Heart failure) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acute Heart failure Emerging Drugs Chapters

This segment of the Acute Heart failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Heart failure Emerging Drugs

Istaroxime: Windtree TherapeuticsIstaroxime is a first-in-class, dual action, agent in clinical development for the treatment of acute decompensated heart failure (ADHF). Istaroxime’s dual mechanism is designed to improve both systolic contractions of the heart as a potent positive inotropic agent that increases contractility through inhibition of Na+/K+-ATPase, as well as its diastolic myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum.

Adrecizumab: AdrenomedThe Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular integrity.

Acute Heart failure: Therapeutic Assessment

This segment of the report provides insights about the different Acute Heart failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Heart failure

There are approx. 10+ key companies which are developing the therapies for Acute Heart failure. The companies which have their Acute Heart failure drug candidates in the most advanced stage, i.e. phase II include, Windtree Therapeutics.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Heart failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Heart failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Heart failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Heart failure drugs.

Acute Heart failure Report Insights

• Acute Heart failure Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Heart failure Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Heart failure drugs?
• How many Acute Heart failure drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Heart failure?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Heart failure therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Heart failure and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Windtree Therapeutics
• Adrenomed
• Arena Pharmaceuticals
• Bristol-Myers Squibb
• Rockwell Medical, Inc.

Key Products

• Istaroxime
• Adrecizumab
• APD418
• CXL-1427
• BMS-986259

This product will be delivered within 2 business days.